Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fred Ledon
Observed name:
Frederic Ledon
Institution:
Avanir Pharmaceuticals (United States)
Observed institutions:
Avanir Pharmaceuticals (United States),
Indiana University School of Medicine
OpenAlex ID:
A5016385768
Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study
2011
·
Stacy Smith
, Steven Fagien
, et al.
·
Journal of the American Academy of Dermatology
·
82
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
2016
·
Flora M. Hammond
, David N. Alexander
, et al.
·
BMC Neurology
·
40
PDF
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM‐II Open Label Study
2018
·
Flora M. Hammond
, William Sauve
, et al.
·
PM&R
·
22
PDF
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results
2015
·
Rachelle S. Doody
, Stephen D’Amico
, et al.
·
CNS Spectrums
·
14
PDF
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial
2018
·
Richard D. Zorowitz
, David N. Alexander
, et al.
·
PM&R
·
7
PDF
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
2016
·
Flora M. Hammond
, David N. Alexander
, et al.
·
BMC Neurology
·
3
PDF
Safety and Tolerability of Dextromethorphan/Quinidine in Older Patients
2017
·
Stephen D'Amico
, David N. Alexander
, et al.
·
American Journal of Geriatric Psychiatry
·
2
An Open-Label Study to Assess Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect (PBA) in Dementia, Stroke and Traumatic Brain Injury: PRISM II Combined Cohort Results for Patients Aged ≥65 Years
2016
·
Flora Hammond
, David N. Alexander
, et al.
·
American Journal of Geriatric Psychiatry
·
2
Abstract 107: Dextromethorphan/Quinidine for Treatment of Pseudobulbar Affect Secondary to Stroke: Results from the PRISM-II Study
2016
·
Richard Zorowitz
, David Alexander
, et al.
·
Stroke
·
2
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Stroke: PRISM-II
2015
·
Richard D. Zorowitz
, David N. Alexander
, et al.
·
Archives of Physical Medicine and Rehabilitation
·
2
Poster 62 Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Traumatic Brain Injury: PRISM‐II
2015
·
Flora Hammond
, William Sauve
, et al.
·
PM&R
·
2
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Traumatic Brain Injury: PRISM-II.
2015
·
Flora Hammond
, William Sauve
, et al.
·
Archives of Physical Medicine and Rehabilitation
·
1
PRISM II: Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Combined Results of a Multicenter Open-Label Study (P2.225)
2016
·
Joao Siffert
, Flora Hammond
, et al.
·
Neurology
P1‐300: Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Comparison of patient‐reported ratings to those of caregiver proxies in a 12‐week open‐label trial (PRISM II)
2015
·
Rachelle S. Doody
, Andrew J. Cutler
, et al.
·
Alzheimer s & Dementia
O4‐09‐06: Dextromethorphan/quinidine for treatment of pseudobulbar affect in patients with dementia: Treatment effects by concomitant antidepressant use in a 12‐week open‐label trial (PRISM II)
2015
·
Rachelle S. Doody
, Stephen D'Amico
, et al.
·
Alzheimer s & Dementia
P3‐290: Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Examination of cns‐ls outcomes in a 12‐week open‐label trial (PRISM II)
2015
·
Rachelle S. Doody
, Stephen D'Amico
, et al.
·
Alzheimer s & Dementia
PRISM II: An Open-Label Study to Assess the Safety, Tolerability, and Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Results from the Alzheimer’s Disease/Dementia Cohort (P7.109)
2015
·
Rachelle Doody
, Stephen D'Amico
, et al.
·
Neurology
PRISM II: An Open-Label Study to Assess the Safety, Tolerability, and Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Results from the Alzheimer's Disease/Dementia Cohort
2015
·
Rachelle S. Doody
, Stephen D'Amico
, et al.
·
American Journal of Geriatric Psychiatry
P4‐359: Prism Ii: an Open‐label Study to Assess the Safety, Tolerability, and Effectiveness of Dextromethorphan 20 Mg/quinidine 10 Mg (nuedexta®) in Pseudobulbar Affect (pba) Secondary to Dementia, Stroke, or Traumatic Brain Injury (tbi)–early Results of Trial
2014
·
Stephen D'Amico
, Andrew J. Cutler
, et al.
·
Alzheimer s & Dementia
Show more works
View as search
Works count:
19
Citation count:
179
H-index:
5
I10-index:
4
Year
Topic
Type